# Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Source: https://onco.cc/trials/nct03736889/  
OnCo record `nct03736889` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tislelizumab in advanced solid tumours, run by BeiGene, now recruiting.

## Summary

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors is a phase 2 interventional study registered as NCT03736889 by BeiGene, with 200 participants planned, started 2018-09-19 and due to reach its primary completion in 2026-11. Interventions recorded: Tislelizumab (BGB-A317).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03736889
- Phase: 2
- Setting: A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
- Sponsor: BeiGene
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT03736889: https://clinicaltrials.gov/study/NCT03736889

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct03736889.json